{"pub": "marketwatch", "url": "https://marketwatch.com/story/mercks-v920-ebola-treatment-granted-priority-review-by-the-fda-2019-09-17?mod=rsswn", "downloaded_at": "2019-09-17 11:25:41.587438+00:00", "title": "Merck's V920 Ebola treatment granted priority review by the FDA", "language": "en", "text": "Merck & Co. Inc. MRK, -0.70% said Tuesday the Food and Drug Administration has accepted the biologics license application (BLA) for its V920 investigational vaccine for Ebola Zaire virus. The drugmaker said the FDA also granted priority review for V920. The company said it will base new investigational supply on a combination of leveraging material from production activities at the planned commercial manufacturing site in Germany and new production at a clinical manufacturing site in the U.S. Merck's stock edged up 0.2% in premarket trading. It has gained 7.4% year to date, while the SPDR Health Care Select Sector ETF XLV, -0.22% has tacked on 5.6% and the Dow Jones Industrial Average DJIA, -0.52% has advanced 16.1%.", "description": "Merck & Co. Inc. said Tuesday the Food and Drug Administration has accepted the biologics license application (BLA) for its V920 investigational vaccine...", "authors": ["Tomi Kilgore", "Reporter"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-09-17"}